Related Experiment Videos
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth
1Department of Biochemistry and Molecular Biology, George Washington University School of Medicine, Washington, DC 20037.
Abstract:
The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIP-hyb) on NSCLC growth were investigated. In vivo, when VIPhyb (10 micrograms, s.c.) was daily injected into nude mice, xenograft formation was significantly inhibited by approximately 80%. In vitro, VIP (100 nM) stimulated colony formation approximately 2-fold, whereas 1 microM VIPhyb inhibited colony formation by approximately 50% when adenocarcinoma cell line NCI-H838 was used. The attenuation of tumor proliferation is receptor mediated, as VIPhyb inhibited specific 125I-labeled VIP binding to cell lines NCI-H157 and NCI-H838 with an IC50 of 0.7 microM. VIP (10 nM) increased the cAMP levels 5-fold when cell line NCI-H838 was used, and 10 microM VIPhyb inhibited the increase in cAMP caused by VIP. Northern blot analysis and radioimmunoassays have shown VIP mRNA and VIP-like immunoreactivity in NSCLC cells. These data suggest that VIP may be a regulatory peptide in NSCLC and that VIPhyb is a VIP receptor antagonist that inhibits proliferation.
Insights
A VIP antagonist (VIP-hyb) significantly inhibited non-small cell lung cancer (NSCLC) growth in vivo and in vitro. This VIP receptor antagonist offers a potential therapeutic strategy for NSCLC by blocking tumor proliferation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Vasoactive intestinal peptide (VIP) receptors are present on NSCLC cells.
- VIP may play a role in regulating NSCLC growth.
Purpose of the Study:
- To investigate the effects of a VIP antagonist (VIP-hyb) on NSCLC growth.
- To determine if VIP-hyb can inhibit tumor proliferation.
- To confirm the receptor-mediated action of VIP-hyb.
Main Methods:
- In vivo studies using nude mice with NSCLC xenografts.
- In vitro studies using NSCLC cell lines (NCI-H838, NCI-H157).
- Assays included colony formation, radioligand binding, cAMP level measurement, Northern blot, and radioimmunoassay.
Main Results:
- VIP-hyb significantly inhibited xenograft formation by approximately 80% in vivo.
- VIP-hyb inhibited NSCLC cell colony formation by approximately 50% in vitro.
- VIP-hyb demonstrated receptor-mediated inhibition of VIP binding and blocked VIP-induced cAMP increase.
Conclusions:
- VIP acts as a regulatory peptide in NSCLC.
- VIP-hyb functions as a VIP receptor antagonist.
- VIP-hyb effectively inhibits NSCLC proliferation, suggesting its potential as a therapeutic agent.